Loading...
BLRX logo

BioLineRx Ltd.NasdaqCM:BLRX Stock Report

Market Cap US$11.3m
Share Price
n/a
1Y-39.9%
7D-6.9%
1D-1.5%
Portfolio Value
​
View

BioLineRx Ltd.

NasdaqCM:BLRX Stock Report

Market Cap: US$11.3m

BioLineRx (BLRX) Stock Overview

A biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. More details

BLRX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Revenue is forecast to grow 63.77% per year

Earnings have grown 24.6% per year over the past 5 years

Risk Analysis

Earnings are forecast to decline by an average of 11.4% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($11M)

Does not have meaningful revenue ($1M)


BLRX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW436,653 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
436,653 investors already sharing narratives
View all narratives

BioLineRx Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for BioLineRx
Historical stock prices
Current Share Price₪2.55
52 Week High₪4.56
52 Week Low₪2.15
Beta0.70
1 Month Change-5.97%
3 Month Change-26.51%
1 Year Change-39.86%
3 Year Change-96.16%
5 Year Change-97.64%
Change since IPO-99.90%

Recent News & Updates

Recent updates

Seeking Alpha • Sep 19

BioLineRx stock slips on $15M securities offering

BioLineRx (NASDAQ:BLRX) shares dropped 30% pre-market on Monday after the biopharmaceutical company announced a $15M securities offering. The firm entered into definitive agreements with several institutional investors for the issuance and sale of 13,636,365 of its American Depositary Shares and warrants to purchase up to 13,636,365 ADSs at a combined purchase price of $1.10 per ADS and associated warrant. Each ADS represents 15 ordinary shares, par value NIS 0.10 per share, of BioLineRx. The warrants will have an exercise price of $1.15/ADS and will be exercisable at any time upon issuance and will expire five years from the date of issuance. Gross proceeds from the offering are expected to be $15M. Net proceeds will be used to facilitate the commercial launch of Motixafortide in autologous stem cell mobilization for multiple myeloma patients and general corporate purposes, which may include working capital and funding clinical trials. The offering is expected to close on or about Sep 21, 2022.
Seeking Alpha • Sep 12

BioLineRx files for FDA approval of motixafortide in stem cell mobilization

BioLineRx (NASDAQ:BLRX) submitted its new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Motixafortide in stem cell mobilization (SCM) for autologous bone marrow transplantation for patients with multiple myeloma. The NDA was backed by data from a phase 3 trial called GENESIS, which had met all main and secondary goals, the company said in a Sept. 12 press release. BioLineRx expects a decision on the NDA acceptance by the FDA in November. BLRX -4.40% to $1.74 premarket Sept. 12.
Seeking Alpha • Aug 16

biolinerx GAAP EPS of -$0.01 beats by $0.08

biolinerx press release (NASDAQ:BLRX): Q2 GAAP EPS of -$0.01 beats by $0.08. Ended the second quarter, with cash and cash equivalents of $43.2 million, sufficient to fund operations, as currently planned, into the first half of 2024.
Seeking Alpha • Jun 29

BioLineRx, GenFleet to co-develop Motixafortide treatment for a type of pancreatic cancer

M.S.Q. Ventures on Wednesday said its client BioLineRx (NASDAQ:BLRX) had entered into an agreement with China-based GenFleet Therapeutics for the co-development of inhibitor Motixafortide to treat a type of pancreatic cancer called pancreatic ductal adenocarcinoma (PDAC). As per the deal, GenFleet will design and run a randomized phase 2b clinical trial that will enroll about 200 first-line metastatic PDAC patients in China. The trial will evaluate the superiority of Motixafortide in combination with anti-PD-1 and chemotherapy vs. chemotherapy alone. U.S.-listed shares of BLRX were down 3.9% at $1.25 in premarket trading.
Seeking Alpha • Jun 30

BioLineRx: A Top Candidate For A Takeover Before 2022 Ends

On May 4, the company crossed successfully a crucial hurdle, putting it en-route toward getting an FDA approval as early as next year. As is the case with all micro-cap biotechs, investors remain skeptical due to the expected cash burn until, surely after, a possible approval. Not only does BioLineRx has sufficient liquidity for the next two years, but there are additional catalysts along the next 18 months. We believe that BLRX has a good chance to be bought out for a stock price in the mid-high teens, possibly before 2022 comes to an end.

Shareholder Returns

BLRXUS BiotechsUS Market
7D-6.9%-4.4%-0.2%
1Y-39.9%39.9%14.8%

Return vs Industry: BLRX underperformed the US Biotechs industry which returned 38.4% over the past year.

Return vs Market: BLRX underperformed the US Market which returned 15.5% over the past year.

Price Volatility

Is BLRX's price volatile compared to industry and market?
BLRX volatility
BLRX Average Weekly Movement7.9%
Biotechs Industry Average Movement9.6%
Market Average Movement6.9%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: BLRX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: BLRX's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200322Phil Serlinwww.biolinerx.com

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions.

BioLineRx Ltd. Fundamentals Summary

How do BioLineRx's earnings and revenue compare to its market cap?
BLRX fundamental statistics
Market capUS$11.26m
Earnings (TTM)-US$6.99m
Revenue (TTM)US$1.39m
8.1x
P/S Ratio
-1.6x
P/E Ratio

Is BLRX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BLRX income statement (TTM)
RevenueUS$1.39m
Cost of RevenueUS$278.00k
Gross ProfitUS$1.11m
Other ExpensesUS$8.10m
Earnings-US$6.99m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.0027
Gross Margin80.03%
Net Profit Margin-502.08%
Debt/Equity Ratio40.3%

How did BLRX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/09 16:49
End of Day Share Price 2026/09/09 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioLineRx Ltd. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael KingCitizens JMP Securities, LLC
Joseph PantginisH.C. Wainwright & Co.
Justin WalshJonesTrading Institutional Services, LLC